Meeting
2023 ASCO Annual Meeting
First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.
Authors
Timothy A. Yap
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Timothy A. Yap , Abdelaziz M. Elhaddad , Rachel N. Grisham , John Turner Hamm , Douglas Kanter Marks , Geoffrey Shapiro , Christophe Le Corre , Jerry Li , Tun Tun Lin , Feng Liu , Lara Malky , Allison R Moreau , Heather Neumann , Dejan Juric , Manish Sharma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04553133
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3010)
DOI
10.1200/JCO.2023.41.16_suppl.3010
Abstract #
3010
Poster Bd #
208
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
First Author: Manish R. Patel
Poster
2022 ASCO Annual Meeting
TWT-203: Phase 1b/2 dose-confirming study of CFI-402257 as a single agent in advanced solid tumors and in combination with fulvestrant in patients with ER+/HER2- advanced breast cancer after disease progression on prior CDK4/6 and endocrine therapy.
First Author: Robert Wesolowski
Poster
2023 ASCO Annual Meeting
First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.
First Author: Timothy A. Yap
Poster
2024 ASCO Annual Meeting
Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study.
First Author: Sonia Pernas